Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sodium Thiosulfate: An Innovative Multi-Target Repurposed Treatment Strategy for Late-Onset Alzheimer's Disease.
Pharmaceuticals (Basel)
December 2024
Department of Physiology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Late-onset Alzheimer's disease (LOAD) is a chronic, multifactorial, and progressive neurodegenerative disease that associates with aging and is highly prevalent in our older population (≥65 years of age). This hypothesis generating this narrative review will examine the important role for the use of sodium thiosulfate (STS) as a possible multi-targeting treatment option for LOAD. Sulfur is widely available in our environment and is responsible for forming organosulfur compounds that are known to be associated with a wide range of biological activities in the brain.
View Article and Find Full Text PDFCisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review.
Antioxidants (Basel)
December 2024
Institute of Pharmacology and Toxicology, Paracelsus Medical University, 5020 Salzburg, Austria.
Cisplatin is an established component of treatment protocols for various solid malignancies but carries a significant potential for serious adverse effects. Ototoxicity from cisplatin treatment is an important dose-limiting toxicity that manifests as bilateral, progressive, irreversible, dose-dependent sensorineural hearing loss, ear pain, tinnitus, and vestibular dysfunction. Despite the recent approval of sodium thiosulphate for the prevention of cisplatin-induced hearing loss (CIHL) in pediatric patients, structured prevention programs are not routinely implemented in most hospitals, and reducing platinum-induced ototoxicity in adults remains an important clinical problem without established treatment options.
View Article and Find Full Text PDFSodium Thiosulfate for Ototoxicity Prevention: A National Review of UK Practice.
Pediatr Blood Cancer
January 2025
Paediatric Oncology Department, Southampton Children's Hospital, Southampton, UK.
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).
Sci Rep
December 2024
Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and angioedema. Sacubitril/valsartan-associated ototoxicity is often underreported in clinical studies and real-world settings.
View Article and Find Full Text PDFOtoprotective Effects of Sodium Thiosulfate by Demographic and Clinical Characteristics: A Report From Children's Oncology Group Study ACCL0431.
Pediatr Blood Cancer
December 2024
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Article Synopsis
- The ACCL0431 trial showed that sodium thiosulfate (STS) effectively reduces cisplatin-induced hearing loss in young patients aged 1-18.
- A secondary analysis revealed that the incidence of hearing loss was significantly lower in those receiving STS (22.4%) compared to those who were only observed (54.0%).
- The best protective effects of STS were seen in younger children (under 5 years) and those with specific cancers like neuroblastoma, indicating the need for tailored treatment strategies based on patient characteristics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!